Landmark Changes in Asthma Management
Learn about landmark changes in asthma management and how you can help your patients make the transition.
The Global Initiative for Asthma (GINA) recommended landmark changes in asthma management in 2019 that has shifted the way healthcare providers and pharmacists provide treatment and care for patients with asthma.
This international panel of experts no longer recommend treating adults and adolescents with mild asthma with short-acting bronchodilators alone. Instead, they recommend patients receive symptom-driven prescriptions or use a corticosteroid-containing inhaler to reduce the risk of severe exacerbations and reduce the reliance on short-acting treatments.
This is an important paradigm shift in asthma management. This course provides you with education and helpful information to empower your patients in making this transition in the management of their asthma.
Upon completion of this course, participants will be able to:
- Describe current global recommendations to help minimize over-use of short-acting beta-agonists as monotherapy and optimize controller therapy.
- Assess the level of control of an asthma patient and identify opportunities in the pharmacy to optimize asthma control for their patients.
Course at a glance:
Who should take this course:
Pharmacists who want to broaden their knowledge in the area of asthma management.